# A Year After Big Pharma’s UK Pull-Back, Stance Still Unclear

September 2025 marked a low point in relations between the United Kingdom government and large pharmaceutical companies, according to a report from Fierce Biotech. Now, one year later, the publication has contacted the companies involved to assess whether their positions have softened. The outcome of those inquiries has not been detailed in the summary, but the question reflects ongoing uncertainty about the state of the UK’s biotech and pharmaceutical investment climate.

**Context for the life sciences sector**

The UK has long been a major hub for pharmaceutical research, manufacturing, and clinical trials. A withdrawal or reduction of activity by Big Pharma can affect drug development pipelines, employment in the life sciences workforce, and the country’s attractiveness for future investment. Tensions between industry and government, often revolving around pricing, regulation, or tax policies, can have ripple effects across the broader biotech ecosystem, including contract research organizations, academic partnerships, and startup funding. Monitoring whether the relationship has improved or remained strained is therefore relevant to anyone tracking the health of the UK life sciences sector.

Source: [original report](https://www.fiercebiotech.com/biotech/year-big-pharmas-pull-back-uk-has-anything-changed)